Treatment of a patient with a group of symptoms, not a group of diagnoses – the potential of citalopram Review article
Article Sidebar
Published:
Sep 30, 2022
Keywords:
citalopram, depression, anxiety symptoms, anxiety-depressive disorders, delusional disorders
Main Article Content
Abstract
Citalopram is an SSRI antidepressant and is widely used for depression, anxiety disorders and sleep disorders. High efficiency combined with a favourable tolerance profile makes citalopram suitable for elderly patients. In this group of patients, however, one should remember to adjust the dose to the patient’s condition and avoid interactions with other drugs commonly used. The paper presents two case reports of the use of citalopram in patients in difficult diagnostic situations.
Article Details
How to Cite
Gładka, A., & Rymaszewska , J. (2022). Treatment of a patient with a group of symptoms, not a group of diagnoses – the potential of citalopram. Medycyna Faktow (J EBM), 15(3(56), 347-352. https://doi.org/10.24292/01.MF.0322.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. WHO Figure: Crude suicide rate (access: 13.06.2021).
2. Beck AT, Rush AJ, Shaw BF et al. Cognitive Therapy of Depression. Guilford Press, New York 1979.
3. Stahl SM. Prescriber’s Guide Seventh Edition. Cambridge University Press. 2021.
4. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998; 51(3): 215-35.
5. Charakterystyka produktu leczniczego: citalopram.
6. Cipriani A, Purgato M, Furukawa TA et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7(7): CD006534. http://doi.org/10.1002/14651858.CD006534.pub2.
7. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive d isorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66. http://doi.org/10.1016/ S0140-6736(17)32802-7.
8. Cipriani A, Purgato M, Furukawa TA et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7(7): CD006534. http://doi.org/10.1002/14651858.CD006534.pub2.
9. Lavretsky H, Reinlieb M, Cyr N St et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015; 172(6): 561-9. http://doi.org/10.1176/appi.ajp.2014.14070889.
10. Zisook S, Trivedi MH, Warden D et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR*D study. J Affect Disord. 2009; 117: 63-73. http://doi.org/10.1016/j.jad.2009.01.002.
11. Porsteinsson AP, Drye LT, Pollock BG et al; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014; 311(7): 682-91. http://doi.org/10.1001/jama.2014.93.
12. Zorick T, Okita K, Mandelkern MA et al. Effects of Citalopram on Cue-Induced Alcohol Craving and Thalamic D2/3 Dopamine Receptor Availability. Int J Neuropsy chopharmacol. 2019; 22(4): 286-91. http://doi.org/10.1093/ijnp/pyz010.
13. Paret C, Niedtfeld I, Lotter T et al. Single-Dose Effects of Citalopram on Neural Responses to Affective Stimuli in Borderline Personality Disorder: A Randomized Clinical Trial. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021; 6(8): 837-45. http://doi.org/10.1016/j.bpsc.2021.02.002.
14. Edes AE, McKie S, Szabo E et al. Increased activation of the pregenual anterior cingulate cortex to citalopram challenge in migraine: an fMRI study. BMC Neurol. 2019; 19(1): 237. http://doi.org/10.1186/s12883-019-1478-0.
15. Arnone D, Wise T, Walker C et al. The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84(Pt A): 152-9.
16. Edinoff AN, Akuly HA, Hanna TA et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021; 13(3): 387-401. http://doi.org/10.3390/neurolint13030038.
17. Bazire S. Psychotropic Drug Directory 2018. The Professionals’ Pocket Handbook and Aide Memoire. Lloyd-Reinhold Publications Limited©Stephen Bazire 2020.
2. Beck AT, Rush AJ, Shaw BF et al. Cognitive Therapy of Depression. Guilford Press, New York 1979.
3. Stahl SM. Prescriber’s Guide Seventh Edition. Cambridge University Press. 2021.
4. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998; 51(3): 215-35.
5. Charakterystyka produktu leczniczego: citalopram.
6. Cipriani A, Purgato M, Furukawa TA et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7(7): CD006534. http://doi.org/10.1002/14651858.CD006534.pub2.
7. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive d isorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66. http://doi.org/10.1016/ S0140-6736(17)32802-7.
8. Cipriani A, Purgato M, Furukawa TA et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7(7): CD006534. http://doi.org/10.1002/14651858.CD006534.pub2.
9. Lavretsky H, Reinlieb M, Cyr N St et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015; 172(6): 561-9. http://doi.org/10.1176/appi.ajp.2014.14070889.
10. Zisook S, Trivedi MH, Warden D et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR*D study. J Affect Disord. 2009; 117: 63-73. http://doi.org/10.1016/j.jad.2009.01.002.
11. Porsteinsson AP, Drye LT, Pollock BG et al; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014; 311(7): 682-91. http://doi.org/10.1001/jama.2014.93.
12. Zorick T, Okita K, Mandelkern MA et al. Effects of Citalopram on Cue-Induced Alcohol Craving and Thalamic D2/3 Dopamine Receptor Availability. Int J Neuropsy chopharmacol. 2019; 22(4): 286-91. http://doi.org/10.1093/ijnp/pyz010.
13. Paret C, Niedtfeld I, Lotter T et al. Single-Dose Effects of Citalopram on Neural Responses to Affective Stimuli in Borderline Personality Disorder: A Randomized Clinical Trial. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021; 6(8): 837-45. http://doi.org/10.1016/j.bpsc.2021.02.002.
14. Edes AE, McKie S, Szabo E et al. Increased activation of the pregenual anterior cingulate cortex to citalopram challenge in migraine: an fMRI study. BMC Neurol. 2019; 19(1): 237. http://doi.org/10.1186/s12883-019-1478-0.
15. Arnone D, Wise T, Walker C et al. The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84(Pt A): 152-9.
16. Edinoff AN, Akuly HA, Hanna TA et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021; 13(3): 387-401. http://doi.org/10.3390/neurolint13030038.
17. Bazire S. Psychotropic Drug Directory 2018. The Professionals’ Pocket Handbook and Aide Memoire. Lloyd-Reinhold Publications Limited©Stephen Bazire 2020.